Clinical trials: Schizoaffective
Bipolar Disorder, Cannabis Use
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
This research study evaluates the effects of an FDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana.
- Conditions
- Bipolar Disorder, Cannabis Use, Schizoaffective Disorder, Bipolar Type, Bipolar I Disorder
- Trial name
- NCT05064319
- Testing
- Gabapentin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Medical University of South Carolina
Schizophrenia / Schizoaffective Disorder, TMS
Efficacy and Safety of Individualized Sequential Accelerated Theta Burst Stimulation in Improving Cognitive Function in Schizophrenia
The goal of this clinical trial is to learn if sequential dual-site accelerated theta burst stimulation (SD-aTBS) targeting the frontoparietal network and default mode network works to improve cognitive function in adults with…
- Conditions
- Schizophrenia / Schizoaffective Disorder, TMS, Cognitive, PET / MR
- Trial name
- NCT07806877
- Testing
- Sequential Dual-Site Accelerated Theta Burst Stimulation (SD-aTBS)
- Volunteers
- 60 people
- Sponsor
- Central South University
Schizophrenia, Schizoaffective Disorder
Cognitive Behavioral Social Skills Training in Early Onset Psychosis
Cognitive-behavioral therapy (CBT) and social skills training (SST) are recommended psychological interventions to improve symptomatology and functional recovery in psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychosis NOS
- Trial name
- NCT03261557
- Testing
- CBT + SST, Psychoeducation, habits and healthy lifestyle
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospital Clinic of Barcelona
Schizophrenia, Schizoaffective
Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia
This study will examine changes in synaptic density with transcranial direct current stimulation (tDCS) in the brains of patients with schizophrenia.
- Trial name
- NCT05435300
- Testing
- PET Scan
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia
Plasma half-life has routinely been used to establish the dosing schedule of antipsychotics; for example, it is recommended that agents with a short plasma half-life be administered multiple times per day.
- Trial name
- NCT02639702
- Testing
- Clozapine
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia;Schizoaffective
The Effects of Non-invasive Brain Stimulation on Treatment Adherence in Schizophrenia
This study seeks to explore the effects of transcranial direct current stimulation (tDCS), a non-invasive method of brain stimulation, as an adjunctive treatment to improve antipsychotic medication adherence in patients with…
- Trial name
- NCT04033679
- Testing
- Active TDCS
- Where
- Canada
- Volunteers
- 106 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Impact of Medication Education on Adherence and Side Effects
Severe mental disorders such as schizophrenia, bipolar disorder, and psychotic depression often require long-term or lifelong medication treatment.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depressive Disorder With Psychotic Features
- Trial name
- MED-ADHERE (NCT07374588)
- Testing
- Medication Education Program, Routine Psychiatric Inpatient Care
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Cumhuriyet University
Schizophrenia, Schizotypal Disorder
The OPUS YOUNG Trial. Early Intervention Versus Treatment as Usual for Adolescents With First-episode Psychosis
The OPUS YOUNG (OY) study investigates the efficacy of early intervention service versus treatment as usual (TAU) for adolescents aged 12-17 years with a first-episode psychosis.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Acute and Transient Psychotic Disorder, Unspecified
- Trial name
- OPUS-YOUNG (NCT04916626)
- Testing
- OPUS YOUNG, Treatment as Usual
- Where
- Denmark
- Volunteers
- 284 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Schizophrenia, Schizoaffective Disorder
Cerebellar Modulation of Cognition in Psychosis
The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I, Psychosis
- Trial name
- NCT06107764
- Testing
- intermittant theta burst stimulation (iTBS), continuous theta burst stimulation (cTBS)
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Mclean Hospital
Schizophrenia, Schizoaffective Disorder
Enhancing Veteran-Clinical Collaboration in VA PRRCs
Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Bipolar Disorder
- Trial name
- EVCC VPRRC (NCT06898879)
- Testing
- Collaborative Decision Skills Training, Leveling Up
- Where
- 3 sites in United States
- Volunteers
- 119 people
- Sponsor
- VA Office of Research and Development
Bipolar I Disorder, Psychosis
Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder
This is a randomized, controlled clinical trial to assess the effects of the ketogenic diet in combination with treatment as usual on brain energy metabolism and psychiatric symptoms in individuals with first episode bipolar…
- Conditions
- Bipolar I Disorder, Psychosis, Schizoaffective Disorder
- Trial name
- NCT06221852
- Testing
- Ketogenic diet, Dietary Guidelines for Americans
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mclean Hospital
Bipolar I Disorder, Schizoaffective Disorder
Open Label Extension Study of NCT06221852
This is a 12-week open-label extension study for participants completing study NCT06221852.
- Conditions
- Bipolar I Disorder, Schizoaffective Disorder, Psychosis
- Trial name
- NCT06558201
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mclean Hospital
Schizophrenia Schizoaffective
Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes
Two of the major features of schizophrenia spectrum illness, negative and cognitive symptoms, have been associated with poor functional outcome and burden of illness.
- Trial name
- NCT05414058
- Testing
- Apo-Methylphenidate ER
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia and Schizoaffective Disorder
A Trial of Group Cognitive Behavioral Therapy for Psychosis (the Feeling Safe Programme)
Schizophrenia is a serious psychiatric disorder characterized by delusions, hallucinations, negative symptoms and disorganized behaviour.
- Trial name
- NCT07408934
- Testing
- Cognitive Behavioral Therapy for Psychosis
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Agitation, Schizophrenia
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in schizophrenia.
- Conditions
- Agitation, Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder
- Trial name
- SERENITY I (NCT04268303)
- Testing
- Sublingual film containing dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Schizoaffective Disorder
Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive…
- Trial name
- NCT06003036
- Testing
- transcranial magnetic stimulation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Deepak K. Sarpal, M.D.
Agitation,Psychomotor, Bipolar I Disorder
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform…
- Conditions
- Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia
- Trial name
- NCT05658510
- Testing
- BXCL501
- Where
- 24 sites in United States
- Volunteers
- 452 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Schizophreniform Disorder
Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode
The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT05890183
- Testing
- Cognitive training, Aerobic Exercise Program, Moderated Online Social Therapy (MOST)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, Los Angeles
Schizophrenia or Schizoaffective
Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia…
- Trial name
- NCT06627413
- Testing
- Lumateperone Capsule, Lumateperone LAI
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizoaffective Disorder, Depressive Type, Bipolar Disorder I
Biocollection on Peripheral Inflammation
Most psychiatric research is based on the nosographic classifications used in current practice. At present, there is no diagnostic or prognostic biomarker for psychiatric pathologies commonly used in clinical practice.
- Conditions
- Schizoaffective Disorder, Depressive Type, Bipolar Disorder I, Bipolar Disorder II
- Trial name
- IBIS-PSY (NCT05934474)
- Testing
- Peripheral venipuncture blood sampling, as part of standard care procedures, Interview with a psychiatrist
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Nantes University Hospital